Recent news on Ceenu

Data Monitoring Committee Recommends Closing Enrollment in ...  -  Dec 21, 2006
news aktuell (Pressemitteilung),CeeNU(R) (lomustine [CCNU], Bristol Myers Squibb) (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) ots Originaltext: Eli Lilly and Company Im

Data Monitoring Committee Recommends Closing Enrollment in ...  -  Dec 21, 2006
PR Newswire (press release),...versus CeeNU(R) (lomustine[CCNU]), a chemotherapy used to treat this disease. The primary endpoint is improvement in progression-free survival.

Data Monitoring Committee Recommends Closing Enrollment in ...  -  Dec 24, 2006
news aktuell (Pressemitteilung),CeeNU(R) (lomustine [CCNU], Bristol Myers Squibb) (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) ots Originaltext: Eli Lilly and Company Im

Data Monitoring Committee Recommends Closing Enrollment in ...  -  Dec 21, 2006
PR Newswire (press release),...versus CeeNU(R) (lomustine[CCNU]), a chemotherapy used to treat this disease. The primary endpoint is improvement in progression-free survival.

Combination of Temodar®, CeeNU®, and Radiation Therapy Promising ...  Sep 21, 2006
...published in the Journal of Clinical Oncology, treatment of newly diagnosed glioblastoma multiforme with Temodar® (temozolomide), CeeNU® (lomustine), and ... -Cancer Consultants



Lilly launches phase III trial in aggressive brain cancer  Mar 10, 2006
...study in recurrent glioblastoma multiforme (GBM), which will compare the efficacy, safety and tolerability of enzastaurin, taken orally, with CeeNU, a common ... - Pharmaceutical Business Review

Eli Lilly Launches Phase III Study Of Investigational Agent To ...  Mar 9, 2006
...multiform (GBM | charts | news | Powerrating), which would compare the efficacy, safety and tolerability of enzastaurin, compared to CeeNU, a common oral ... - Trading Markets

Temodar® and Thalomid® Effective for Metastatic Neuroendocrine ...  Mar 21, 2006
Chemotherapy response rates are low and some of the agents studied include 5-fluorouracil, BiCNU® (carmustine), CeeNU® (lomustine), doxorubicin, dacarbazine ... - Cancer Consultants

Lilly Launches Phase III Trial of Targeted Cancer Agent  Mar 9, 2006
...label registration study in recurrent GBM, which will compare the efficacy, safety and tolerability of enzastaurin, taken orally, versus CeeNU(R) (lomustine ... - news aktuell (Pressemitteilung)

Lilly starts phase 3 trial of enzastaurin  Mar 9, 2006
...with the rare but deadly cancer known as glioblastoma multiforme will be treated either with enzastaurin or the common chemotherapeutic agent CeeNU in the ... - United Press International

Eli Lilly Launches Phase III Study Of Enzastaurin For Brain Tumor ...  Mar 9, 2006
...open label registration study named STEERING will compare the efficacy, safety and tolerability of enzastaurin, taken orally, against CeeNU , a common oral ... - Trading Markets

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional